Oral Contraceptive Pills Market Report 2025

The oral contraceptive pills market size has grown rapidly in recent years. It will grow from $26.82 billion in 2024 to $30.7 billion in 2025 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to increasing awareness, rising women's health concerns, government initiatives, changing lifestyles, market expansion.

The oral contraceptive pills market size is expected to see rapid growth in the next few years. It will grow to $54.21 billion in 2029 at a compound annual growth rate (CAGR) of 15.3%. The growth in the forecast period can be attributed to growing population, women's empowerment, rising healthcare expenditure, advancements in healthcare infrastructure, expanding product portfolio. Major trends in the forecast period include focus on minimizing side effects and hormonal disruption, emergence of non-hormonal and natural contraceptive alternatives, shift towards continuous and tailored contraceptive regimens, increasing awareness and education initiatives, rise in female empowerment and involvement in contraceptive choices.

The anticipated rise in unintended pregnancies is expected to be a driving force behind the growth of the oral contraceptive pills market in the upcoming years. Unintended pregnancies, characterized by pregnancies that are not planned or desired, have shown a substantial decrease in rates of unwanted pregnancy and abortion when women are provided with a one-year prescription of oral contraceptives, as indicated by a study conducted by the University of California, San Francisco (UCSF). According to the World Health Organization (WHO), approximately 74 million women in low-middle-income economies globally experience unplanned pregnancies each year. The WHO's research highlights that 4,794 women had unintended pregnancies after discontinuing the use of contraceptives. Thus, the imperative to prevent unintended pregnancies is a key factor driving the growth of the oral contraceptive pills market.

The increasing healthcare expenditure is anticipated to drive the growth of the oral contraceptive pill market in the future. Healthcare expenditure refers to the total resources, including financial investments, allocated to healthcare services and products within a defined timeframe. An increase in healthcare expenditure improves overall access to healthcare, facilitating greater adoption of oral contraceptive pills through enhanced access to family planning services, consultations, and affordable prescriptions, thereby supporting market growth. For example, in May 2023, the Office for National Statistics, a UK-based national statistics organization, reported that UK healthcare expenditure reached approximately $354.88 billion (£283 billion) in 2022, marking a nominal increase of 0.7% compared to 2021. Thus, the rise in healthcare expenditures is contributing to the growth of the oral contraceptive pills market.

Key institutes and companies in the oral contraceptive pill sector are actively engaged in developing innovative solutions, exemplified by HRA Pharma, a France-based healthcare company. In July 2022, HRA Pharma introduced Opill, an over-the-counter birth control pill, and applied for approval from the Food and Drug Administration in the United States. Opill, a progestin-based contraceptive, aims to provide easy access to contraception without unnecessary obstacles.

Prominent companies in the oral contraceptive pill market are also investing in innovative products, including progestin-only oral contraceptives, to cater to a broader customer base, increase sales, and boost revenue. Progestin-only oral contraceptives contain only a synthetic form of the hormone progestin. Perrigo Company PLC, an Ireland-based manufacturer of oral contraceptive pills, secured U.S. Food and Drug Administration (FDA) approval for Opill in July 2023. Opill, the first over-the-counter birth control pill in the United States, not only offers effective pregnancy prevention but also revolutionizes contraception access by being available without a prescription. This development underscores Perrigo's commitment to transformative solutions that enhance lives and exemplifies its dedication to pioneering impactful innovations in healthcare.

In April 2023, Marksans Pharma, an India-based pharmaceutical company, completed the acquisition of Teva Pharmaceutical Industries Ltd.'s manufacturing facility for an undisclosed amount. This acquisition provides Marksans with ownership of a 47,597-square-meter facility, effectively doubling its current production capacity in India to 8 billion units per year. The expanded facility will be utilized for manufacturing various pharmaceutical products, including tablets, hard and soft gel capsules, ointments, liquids, and creams, with Teva Pharmaceutical Industries Ltd. being known for its manufacturing of oral contraceptive pills.

Major companies operating in the oral contraceptive pills market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Abbvie Inc., Bayer AG, Zydus Lifesciences Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Inc., Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Pharmaceuticals Inc., Glenmark Pharmaceuticals, Mankind Pharma Ltd., Mayne Pharma, HLL Lifecare Limited, Famy Care Ltd., Mylan N.V., Novartis AG, GlaxoSmithKline plc, Piramal Enterprises Ltd., Syzygy Healthcare, V Care Pharma.

North America was the largest region in the oral contraceptive pills market in 2024. The Middle East is expected to be the largest growing region in the forecast period. The regions covered in the oral contraceptive pills market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oral contraceptive pills market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Oral contraceptive pills are tablets designed for contraception, containing hormones that inhibit the release of eggs from the ovaries. Typically, these pills contain both progestin and estrogen. Commonly known as birth control pills, they consist of hormones that prevent the ovaries from releasing eggs. The majority of oral contraceptives incorporate both estrogen and progestin.

The market for oral contraceptive pills is categorized by type into combination, progestin-only, and others, by category into generic and branded, and by distribution channel into hospital pharmacy, retail pharmacy, clinics, online channels, public channels and NGOs, among others.

The oral contraceptive pills market research report is one of a series of new reports that provides oral contraceptive pills market statistics, including oral contraceptive pills industry global market size, regional shares, competitors with an oral contraceptive pills market share, detailed oral contraceptive pills market segments, market trends and opportunities, and any further data you may need to thrive in the oral contraceptive pills industry. This oral contraceptive pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral contraceptive pills market consists of sales of combined estrogen-progesterone, progesterone-only, and continuous or extended use pill. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.